TENELIGLIPTIN 20mg. IP

An antihyperglycemic agent used in the management of type 2 diabetes. (Sanjay Sharma, 2020) Produces absolute reductions in glycated hemoglobin levels. (Xiaoxuan Li, 2018) Improves blood glucose levels and β-cells function with a low risk of hypoglycemia in patients with type 2 diabetes. (Xiaoxuan Li, 2018) Shows statistically significant reductions in glycosylated hemoglobin and postprandial glucose in patients with type 2 diabetes mellitus. (Piyush Agarwal, 2018) Ameliorates blood glucose levels over 24 h without hypoglycemia. (T Eto, 2012) Exerts a beneficial effect on pancreatic β-cells and improves pancreatic function. (Xiaoxuan Li X. H., 2018) A valuable treatment option for type 2 diabetes mellitus patients who are inadequately glycemic controlled. (Xiaoxuan Li X. H., 2018) A well-tolerated medicine in individuals with any stage of renal impairment from normal to end-stage renal disease. (Masakazu Haneda, 2018) A promising antidiabetic drug for glycemic control in type 2 diabetes patients undergoing hemodialysis. (Noritsugu Wada, 2015) Possesses a high potency of inhibiting dipeptidyl peptidase-4 activity as compared to sitagliptin, saxagliptin, alogliptin, linagliptin, and vildagliptin. (Seiichi Tanaka, 2014)